首页> 美国卫生研究院文献>Clinical and Molecular Allergy : CMA >Clinical management expectations and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain
【2h】

Clinical management expectations and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain

机译:在西班牙的常规临床实践条件下使用SQ标准化草过敏原片治疗中度至重度变应性鼻结膜炎的患者的临床管理期望和满意度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundSublingual immunotherapy has been proven as a well-tolerated and effective treatment for allergic rhinitis. Within this type of treatment, GRAZAX® is the most documented product in terms of safety and efficacy. The objective of this study was to identify the patients’ expectations and level of treatment satisfaction, as well as the clinical management of patients with moderate/severe allergic rhinoconjunctivitis treated with GRAZAX®.
机译:背景舌下免疫疗法已被证明是过敏性鼻炎的一种耐受良好的有效疗法。在这种类型的治疗中,就安全性和有效性而言,GRAZAX ®是记录最丰富的产品。这项研究的目的是确定患者对GRAZAX ®治疗的中/重度变应性鼻结膜炎的期望和治疗满意度水平以及临床管理。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号